| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2017-12-10 | avapritinib (BLU-285) | advanced systemic mastocytosis | 1 | Blueprint Medicines (USA - MA) | Rare diseases - Hematological diseases |
| 2017-12-10 | Elocta®/Eloctate® (long-lasting recombinant Factor VIII Fc fusion protein - rFVIIIFc - efmoroctocog alfa) | hemophilia A | 3 | Bioverativ (USA - CA) Swedish Orphan Biovitrum SOBI (Sweden) | Rare diseases - Genetic diseases - Hematological diseases |
| 2017-12-10 | Yescarta™ (axicabtagene ciloleucel) (KTE-C19) (autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3 zeta chimeric antigen receptor) | refractory diffuse large B cell lymphoma, refractory primary mediastinal B cell lymphoma, refractory transformed follicular lymphoma | 1-2 | Kite Pharma (USA - CA) | Cancer - Oncology - Rare diseases |
| 2017-12-10 | Adcetris® (brentuximab vedotin) | Hodgkin lymphoma | 3 | Seattle Genetics (USA - WA) | Cancer - Oncology |
| 2017-12-10 | Elocta™/Eloctate™ (recombinant factor VIII Fc fusion protein - rFVIIIFc) | hemophilia A | 3 | BiogenIdec (USA) Swedish Orphan Biovitrum SOBI (Sweden) | Hematologic diseases - Genetic diseases |
| 2017-12-09 | Sprycel® (dasatinib) | newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) | 2 | BMS (USA - NY) | Cancer - Oncology |
| 2017-12-09 | chimeric antigen receptor (CAR)-targeted CD8alphabeta+ T cells | preclinical | Fate Therapeutics (USA - CA) | Cancer - Oncology | |
| 2017-12-09 | Adcetris® (brentuximab vedotin) | CD30-expressing cutaneous T-cell lymphoma (CTCL) | 3 | Millenium Pharmaceuticals (USA - MA) Seattle Genetics (USA - WA), wholly owned subsidiaries of Takeda Pharmaceutical (Japan) | Cancer - Oncology |
| 2017-12-09 | IMGN779 | acute myeloid leukemia, refractory acute myeloid leukemia | 1 | immunogen (USA - MA) | Cancer - Oncology |
| 2017-12-09 | emicizumab (ACE910 - anti-factor IXa x anti-factor X humanized bispecific antibody) | hemophilia A | 3 | Roche (Switzerland) | Rare diseases - Genetic diseases - Hematological diseases |
| 2017-12-09 | emicizumab (ACE910 - anti-factor IXa x anti-factor X humanized bispecific antibody) | hemophilia A | 3 | Roche (Switzerland) | Rare diseases - Genetic diseases - Hematological diseases |
| 2017-12-09 | BMN 270 - valoctocogene roxaparvovec- adeno-associated viral vector serotype 5 containing a B-domain deleted variant of human coagulation factor VIII gene | hemophilia A | 1-2 | Biomarin Pharmaceutical (USA - CA) | Rare diseases - Genetic diseases - Hematological diseases |
| 2017-12-09 | AMT-061 | severe and moderately severe hemophilia B | preclinical | Uniqure (The Netherlands) | Rare diseases - Genetic diseases - Hematological diseases |
| 2017-12-08 | Ibrance® (palbociclib) | postmenopausal women with ER+, HER2- metastatic breast cancer | 3 | Pfizer (USA - NY) | Cancer - Oncology |
| 2017-12-08 | Ery-asp®/Graspa® (eryaspase - L-asparaginase loaded erythrocytes) | acute myeloid leukemia | 2b | Erytech Pharma (France) | Cancer - Oncology |
| 2017-12-07 | CTX001 | Beta-thalassemia | 1-2 | Crispr Therapeutics (Switzerland - UK) | Rare diseases - Genetic diseases - Hematological diseases |
| 2017-12-07 | PCM-075 (1-(2-hydroxyethyl)-8-{[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy) phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide fumarate salt) and Zytiga® (abiraterone acetate) | triple-negative breast cancer (TNBC) | preclinical | Trovagene (USA - CA) | Cancer - Oncology |
| 2017-12-07 | emicizumab (ACE910 - anti-factor IXa x anti-factor X humanized bispecific antibody) | hemophilia A | 3 | Roche (Switzerland) | Rare diseases - Genetic diseases - Hematological diseases |
| 2017-12-07 | Tedopi® (OSE2101) | non-small cell lung cancer | 3 | OSE Pharma (France) now OSE Immunotherapeutics | Cancer - Oncology |
| 2017-12-06 | SPK-8011 | hemophilia A | 1-2 | Spark Therapeutics (USA - PA) | Rare diseases - Genetic diseases - Hematological diseases |
